415 related articles for article (PubMed ID: 24268735)
1. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
4. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
5. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
Sadeghi F; Bokharaei-Salim F; Salehi-Vaziri M; Monavari SH; Alavian SM; Salimi S; Vahabpour R; Keyvani H
J Med Virol; 2014 Sep; 86(9):1499-506. PubMed ID: 24889558
[TBL] [Abstract][Full Text] [Related]
6. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
7. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
9. Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients.
Ozaras R; Tahan V; Ozbay G; Ozturk R; Yenice N; Celikel ÇA; Midilli K; Gucin Z; Fincanci M; Tozun N; Senturk H; Osme A; Tabak F; Mert A
Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1057-62. PubMed ID: 26011229
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
[TBL] [Abstract][Full Text] [Related]
11. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
Malone DC; Tran TT; Poordad FF
J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
[TBL] [Abstract][Full Text] [Related]
14. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection.
Azam S; Manzoor S; Imran M; Ashraf J; Ashraf S; Resham S; Ghani E
Viral Immunol; 2015 May; 28(4):222-8. PubMed ID: 25798684
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Elefsiniotis IS; Vezali E; Mihas C; Saroglou G
Intervirology; 2009; 52(5):247-51. PubMed ID: 19602898
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
[TBL] [Abstract][Full Text] [Related]
18. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
19. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation.
Chen PL; Easton A
J Vasc Res; 2008; 45(2):111-22. PubMed ID: 17940338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
